These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

637 related items for PubMed ID: 23069923

  • 1. Correlation of [11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy.
    Breeuwsma AJ, Rybalov M, Leliveld AM, Pruim J, de Jong IJ.
    Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):440-6. PubMed ID: 23069923
    [Abstract] [Full Text] [Related]

  • 2. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P, Ceci F, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Pettinato C, Celli M, Lodi F, Fanti S.
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [Abstract] [Full Text] [Related]

  • 3. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, Franceschelli A, Martorana G, Manferrari F, Fanti S.
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [Abstract] [Full Text] [Related]

  • 4. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G, Picchio M, Parra RG, Briganti A, Gianolli L, Montorsi F, Messa C.
    Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
    [Abstract] [Full Text] [Related]

  • 5. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [Abstract] [Full Text] [Related]

  • 6. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy.
    Giovacchini G, Picchio M, Garcia-Parra R, Briganti A, Abdollah F, Gianolli L, Schindler C, Montorsi F, Messa C, Fazio F.
    J Nucl Med; 2014 Feb; 55(2):233-41. PubMed ID: 24408897
    [Abstract] [Full Text] [Related]

  • 7. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.
    Marzola MC, Chondrogiannis S, Ferretti A, Grassetto G, Rampin L, Massaro A, Castellucci P, Picchio M, Al-Nahhas A, Colletti PM, Marcolongo A, Rubello D.
    Clin Nucl Med; 2013 Jan; 38(1):e26-32. PubMed ID: 23242060
    [Abstract] [Full Text] [Related]

  • 8. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
    Goldstein J, Even-Sapir E, Ben-Haim S, Saad A, Spieler B, Davidson T, Berger R, Weiss I, Appel S, Lawrence YR, Symon Z.
    Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
    [Abstract] [Full Text] [Related]

  • 9. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
    Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, Allegri V, Montini GC, Ambrosini V, Boschi S, Martorana G, Marzola MC, Fanti S.
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
    [Abstract] [Full Text] [Related]

  • 10. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.
    Schilling D, Schlemmer HP, Wagner PH, Böttcher P, Merseburger AS, Aschoff P, Bares R, Pfannenberg C, Ganswindt U, Corvin S, Stenzl A.
    BJU Int; 2008 Aug; 102(4):446-51. PubMed ID: 18410442
    [Abstract] [Full Text] [Related]

  • 11. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.
    Ceci F, Castellucci P, Mamede M, Schiavina R, Rubello D, Fuccio C, Ambrosini V, Boschi S, Martorana G, Fanti S.
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):149-55. PubMed ID: 23151910
    [Abstract] [Full Text] [Related]

  • 12. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
    Graziani T, Ceci F, Castellucci P, Polverari G, Lima GM, Lodi F, Morganti AG, Ardizzoni A, Schiavina R, Fanti S.
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
    [Abstract] [Full Text] [Related]

  • 13. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer.
    Rybalov M, Breeuwsma AJ, Leliveld AM, Pruim J, Dierckx RA, de Jong IJ.
    World J Urol; 2013 Apr; 31(2):319-23. PubMed ID: 22814886
    [Abstract] [Full Text] [Related]

  • 14. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [Abstract] [Full Text] [Related]

  • 15. Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up.
    Winter A, Henke RP, Wawroschek F.
    BMC Urol; 2015 Feb 21; 15(1):10. PubMed ID: 25881245
    [Abstract] [Full Text] [Related]

  • 16. The use of 68  Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer.
    Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B, Gianduzzo T.
    BJU Int; 2016 Oct 21; 118 Suppl 3():49-55. PubMed ID: 27659411
    [Abstract] [Full Text] [Related]

  • 17. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.
    Int J Radiat Oncol Biol Phys; 2005 Mar 01; 61(3):714-24. PubMed ID: 15708249
    [Abstract] [Full Text] [Related]

  • 18. 11C-choline PET/CT predicts survival in prostate cancer patients with PSA < 1 NG/ml.
    Giovacchini G, Guglielmo P, Mapelli P, Incerti E, Gajate AMS, Giovannini E, Riondato M, Briganti A, Gianolli L, Ciarmiello A, Picchio M.
    Eur J Nucl Med Mol Imaging; 2019 Apr 01; 46(4):921-929. PubMed ID: 30631911
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
    Evangelista L, Cuppari L, Guttilla A, Gardi M, Agostini A, Ruggera L, Basso U, Saladini G.
    Nucl Med Commun; 2018 Mar 01; 39(3):260-267. PubMed ID: 29381584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.